Provided by Tiger Trade Technology Pte. Ltd.

Cullinan Therapeutics

21.82
+0.14000.65%
Post-market: 21.820.00000.00%19:30 EDT
Volume:617.37K
Turnover:13.50M
Market Cap:1.40B
PE:-6.29
High:22.37
Open:21.62
Low:21.16
Close:21.68
52wk High:22.54
52wk Low:5.68
Shares:64.35M
Float Shares:48.08M
Volume Ratio:0.80
T/O Rate:1.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4680
EPS(LYR):-3.7236
ROE:-50.30%
ROA:-31.36%
PB:4.36
PE(LYR):-5.86

Loading ...

Cullinan Therapeutics Inc: Cln-978 (Cd19 Tce) Eular Data Demonstrated Potential for Immune Reset, Including Remissions, in Both Sle and Ra

THOMSON REUTERS
·
Jun 10

Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases

GlobeNewswire
·
Jun 10

Cullinan Showcases Promising CLN-978 Phase 1 Autoimmune Data

TIPRANKS
·
Jun 08

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Amylyx Pharmaceuticals Inc (AMLX) and Cullinan Management (CGEM)

TIPRANKS
·
Jun 08

Cullinan Therapeutics Shares Rise on Positive Early Trial Data for Autoimmune Drug

Dow Jones
·
Jun 08

Cullinan Therapeutics Price Target Maintained With a $30.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 08

Analysts Conflicted on These Healthcare Names: Cullinan Management (CGEM) and Pfizer (PFE)

TIPRANKS
·
Jun 08

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), GMR Solutions, Inc. Class A (GMRS) and Cullinan Management (CGEM)

TIPRANKS
·
Jun 08

Cullinan Therapeutics presents clinical data for CLN-978

TIPRANKS
·
Jun 08

Cullinan Therapeutics Inc -Cln-978 Shows Favorable Safety Profile With Single Target Doses up to 30 ΜG as Well as Initial Multi-Dose Regimen

THOMSON REUTERS
·
Jun 06

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

GlobeNewswire
·
Jun 06

Cullinan’s CLN-978 Lupus Study Opens a New Autoimmune Path for CGEM Investors

TIPRANKS
·
Jun 06

Cullinan Therapeutics to present initial multi-dose clinical data for CLN-978 in rheumatoid arthritis study

Reuters
·
May 26

Stifel Nicolaus Reaffirms Their Buy Rating on Cullinan Management (CGEM)

TIPRANKS
·
May 25

Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and Cullinan Management (CGEM)

TIPRANKS
·
May 20

Cullinan post-EULAR share pullback ‘unwarranted,’ says Clear Street

TIPRANKS
·
May 20

Cullinan Therapeutics wins FDA orphan drug designation for CLN-049 in relapsed AML

Reuters
·
May 19

Cullinan Therapeutics Receives FDA Orphan Drug Designation for Cln-049, a Novel Flt3xcd3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia

THOMSON REUTERS
·
May 19

Cullinan Therapeutics Price Target Maintained With a $38.00/Share by BTIG

Dow Jones
·
May 19

Analysts Offer Insights on Healthcare Companies: Gossamer Bio (GOSS) and Cullinan Management (CGEM)

TIPRANKS
·
May 19